Avidity Biosciences Share Price (NASDAQ: RNA)

$46.49

▲

0.42

(0.91%)

Last updated on August 16, 2025 at 1:29 AM IST

$₹

Check the interactive Avidity Biosciences Stock chart to analyse performance

Avidity Biosciences stock performance

as on August 16, 2025 at 1:29 AM IST

Today's Low:$45.50
Today's High:$47.50
$46.49
2.13%
Downside
Day's Volatility :4.21%
Upside
2.13%
52 Weeks Low:$21.51
52 Weeks High:$56.00
$46.49
53.73%
Downside
52 Weeks Volatility :61.59%
Upside
16.98%

Avidity Biosciences Stock Returns

Period	Avidity Biosciences Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	54.14%	2.3%	0.0%
6 Months	45.56%	-5.9%	0.0%
1 Year	2.6%	-10.9%	0.0%
3 Years	117.56%	2.3%	-11.0%

Avidity Biosciences Inc Key Stats

Check Avidity Biosciences key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$46.07
Open	$45.84
Today's High	$47.5
Today's Low	$45.5
Market Capitalization	$5.9B
Today's Volume	$2.8M
52 Week High	$56.0
52 Week Low	$21.51
Revenue TTM	$10.7M
EBITDA	$-518.7M
Earnings Per Share (EPS)	$-3.56
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-37.76%

Stock Returns calculator for Avidity Biosciences Stock including INR - Dollar returns

The Avidity Biosciences stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Avidity Biosciences investment value today

Current value as on today

₹1,06,611

Returns

₹6,611

(+6.61%)

Returns from Avidity Biosciences Stock

₹2,401 (+2.4%)

Dollar Returns*

₹4,210 (+4.21%)

Indian investors sentiment towards Avidity Biosciences Stock

181%

Period: Jul 17, 2025 to Aug 16, 2025. Change in 30 Days versus previous period

Search interest for Avidity Biosciences Stock from India on INDmoney has increased by 181% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Avidity Biosciences Inc

Name
Holdings %
Alethea Capital Management, LLC
0.33%

Analyst Recommendation on Avidity Biosciences Stock

Rating

Trend

Buy

91%Buy

8%Hold

0%Sell

Based on 12 Wall street analysts offering stock ratings for Avidity Biosciences(by analysts ranked 0 to 5 stars)

Avidity Biosciences Share Price Target

What analysts predicted

Upside of 43.88%

Target:

$66.89

Current:

$46.49

Avidity Biosciences share price target is $66.89, a slight Upside of 43.88% compared to current price of $46.49 as per analysts' prediction.

Avidity Biosciences Stock Insights

Price Movement
In the last 1 month, RNA stock has moved up by 36.8%
Increasing Revenue
Revenue is up for the last 2 quarters, 1.57M → 3.84M (in $), with an average increase of 59.1% per quarter
Decreasing Net Profit
Netprofit is down for the last 9 quarters, -47.02M → -157.31M (in $), with an average decrease of 16.7% per quarter
RNA vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 67.4% return, outperforming this stock by 63.8%
Price to Sales
ForRNA every $1 of sales, investors are willing to pay $554.5, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $23.6 for every $1 of sales.

Avidity Biosciences Inc Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$2.3M	↑ 511.87%
Net Income	$-32.1M	↑ 169.16%
Net Profit Margin	-1.4K%	↑ 1763.69%

	FY20	Y/Y Change
Revenue	$6.8M	↑ 192.67%
Net Income	$-44.0M	↑ 36.93%
Net Profit Margin	-648.03%	↑ 737.09%

	FY21	Y/Y Change
Revenue	$9.3M	↑ 37.41%
Net Income	$-117.4M	↑ 166.86%
Net Profit Margin	-1.3K%	↓ 610.49%

	FY22	Y/Y Change
Revenue	$9.2M	↓ 1.09%
Net Income	$-169.1M	↑ 44.05%
Net Profit Margin	-1.8K%	↓ 574.49%

	FY23	Y/Y Change
Revenue	$9.6M	↑ 3.64%
Net Income	$-212.2M	↑ 25.52%
Net Profit Margin	-2.2K%	↓ 386.86%

	FY24	Y/Y Change
Revenue	$10.9M	↑ 13.99%
Net Income	$-322.3M	↑ 51.87%
Net Profit Margin	-3.0K%	↓ 737.84%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$3.5M	↑ 61.56%
Net Income	$-68.9M	↑ 13.92%
Net Profit Margin	-1.9K%	↑ 812.77%

	Q2 FY24	Q/Q Change
Revenue	$2.0M	↓ 42.28%
Net Income	$-70.8M	↑ 2.81%
Net Profit Margin	-3.5K%	↓ 1518.35%

	Q3 FY24	Q/Q Change
Revenue	$2.3M	↑ 14.23%
Net Income	$-80.4M	↑ 13.57%
Net Profit Margin	-3.4K%	↑ 20.06%

	Q4 FY24	Q/Q Change
Revenue	$3.0M	↑ 27.27%
Net Income	$-102.3M	↑ 27.19%
Net Profit Margin	-3.4K%	↑ 2.18%

	Q1 FY25	Q/Q Change
Revenue	$1.6M	↓ 47.09%
Net Income	$-115.8M	↑ 13.22%
Net Profit Margin	-7.4K%	↓ 3920.49%

	Q2 FY25	Q/Q Change
Revenue	$3.8M	↑ 144.56%
Net Income	$-157.3M	↑ 35.88%
Net Profit Margin	-4.1K%	↑ 3270.72%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$-12.2M	↑ 51.67%

	FY20	Y/Y Change
Profit	$6.8M	↓ 155.54%

	FY21	Y/Y Change
Profit	$9.3M	↑ 37.41%

	FY22	Y/Y Change
Profit	$9.2M	↓ 1.09%

	FY23	Y/Y Change
Profit	$7.5M	↓ 19.13%

	FY24	Y/Y Change
Profit	$10.9M	↑ 46.09%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$2.9M	↑ 83.9%

	Q2 FY24	Q/Q Change
Profit	$1.4M	↓ 53.2%

	Q3 FY24	Q/Q Change
Profit	$2.3M	↑ 72.02%

	Q4 FY24	Q/Q Change
Profit	$3.0M	↑ 27.27%

	Q1 FY25	Q/Q Change
Profit	$1.6M	↓ 47.09%

	Q2 FY25	Q/Q Change
Profit	$3.0M	↑ 92.82%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$2.5M	↓ 125.79%
Investing Cash Flow	$-235.0K	↑ 379.59%
Financing Cash Flow	$89.2M	↑ 1634.7%

	FY20	Y/Y Change
Operating Cash Flow	$-37.1M	↓ 1590.64%
Investing Cash Flow	$-7.8M	↑ 3212.77%
Financing Cash Flow	$272.0M	↑ 204.86%

	FY21	Y/Y Change
Operating Cash Flow	$-94.8M	↑ 155.44%
Investing Cash Flow	$-82.5M	↑ 959.95%
Financing Cash Flow	$176.3M	↓ 35.19%

	FY22	Y/Y Change
Operating Cash Flow	$-136.3M	↑ 43.72%
Investing Cash Flow	$-190.0M	↑ 130.2%
Financing Cash Flow	$346.2M	↑ 96.34%

	FY23	Y/Y Change
Operating Cash Flow	$-119.1M	↓ 12.63%
Investing Cash Flow	$-130.1M	↓ 31.53%
Financing Cash Flow	$93.9M	↓ 72.89%

	FY24	Y/Y Change
Operating Cash Flow	$-300.9M	↑ 152.7%
Investing Cash Flow	$-854.2M	↑ 556.72%
Financing Cash Flow	$1.2B	↑ 1170.3%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-70.4M	↓ 526.52%
Investing Cash Flow	$-32.7M	↓ 164.16%
Financing Cash Flow	$389.4M	↑ 1121.18%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$-65.0M	↓ 7.64%
Investing Cash Flow	$-274.9M	↑ 739.37%
Financing Cash Flow	$446.7M	↑ 14.71%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$-65.6M	↑ 0.94%
Investing Cash Flow	$-482.4M	↑ 75.51%
Financing Cash Flow	$342.5M	↓ 23.34%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$-99.9M	↑ 52.21%
Investing Cash Flow	$-64.2M	↓ 86.7%
Financing Cash Flow	$13.7M	↓ 95.99%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$-124.8M	↑ 24.99%
Investing Cash Flow	$157.2M	↓ 344.95%
Financing Cash Flow	$1.9M	↓ 85.89%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$-199.7M	↑ 59.95%
Investing Cash Flow	$185.5M	↑ 18.0%
Financing Cash Flow	$3.8M	↑ 94.79%

Avidity Biosciences Technicals Summary

Sell

Neutral

Buy

Avidity Biosciences is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Avidity Biosciences Inc Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Avidity Biosciences Inc	37.97%	45.56%	2.6%	117.56%	107.85%
Regeneron Pharmaceuticals, Inc.	7.02%	-14.62%	-51.49%	-7.08%	-6.14%
Beone Medicines Ltd	9.17%	35.05%	67.05%	80.83%	38.63%
Vertex Pharmaceuticals Incorporated	-14.57%	-15.0%	-19.51%	33.48%	44.78%
Alnylam Pharmaceuticals, Inc.	40.09%	79.61%	63.59%	100.95%	220.92%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Avidity Biosciences Inc	NA	NA	0.0	-4.39	-0.38	-0.24	NA	9.88
Regeneron Pharmaceuticals, Inc.	14.03	14.03	1.14	39.47	0.15	0.07	0.0	287.55
Beone Medicines Ltd	NA	NA	NA	2.43	-0.05	-0.01	NA	34.32
Vertex Pharmaceuticals Incorporated	27.78	27.78	0.58	18.05	0.23	0.13	NA	67.02
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	3.92	-2.58	-0.03	NA	1.91

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Avidity Biosciences Inc	Buy	$5.9B	107.85%	NA	0.0%
Regeneron Pharmaceuticals, Inc.	Buy	$59.0B	-6.14%	14.03	31.37%
Beone Medicines Ltd	NA	$37.5B	38.63%	NA	-3.89%
Vertex Pharmaceuticals Incorporated	Buy	$100.1B	44.78%	27.78	31.86%
Alnylam Pharmaceuticals, Inc.	Buy	$58.0B	220.92%	NA	-12.96%

Avidity Biosciences Dividend announcements

Avidity Biosciences Earnings
Avidity Biosciences’s price-to-earnings ratio stands at None

About Avidity Biosciences Inc

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics called antibody oligonucleotide conjugates (AOCs). Its AOC platform is designed to combine the specificity of monoclonal antibodies with the precision of RNA therapeutics to target the root cause of diseases previously untreatable with such therapeutics. The company's pipeline has three programs in registrational clinical trials, such as Delpacibart etedesiran, which is in Phase 3 development stage for the treatment of people with myotonic dystrophy type 1; Delpacibart braxlosiran that is in Phase 1/2 development stage for treating facioscapulohumeral muscular dystrophy; and Delpacibart zotadirsen, which is in the Phase 2 EXPLORE44 open-label extension study for the treatment of Duchenne muscular dystrophy. The company is also developing precision cardiology candidates targeting rare genetic cardiomyopathies, including AOC 1086 for phospholamban cardiomyopathy and AOC 1072 for protein kinase AMP-activated non-catalytic subunit gamma 2 syndrome. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

Organization	Avidity Biosciences
Employees	391
CEO	Ms. Sarah Boyce
Industry	Health Technology

Key Management of Avidity Biosciences Inc

Name	Title
Dr. Troy Edward Wilson J.D., Ph.D.	Co-Founder & Independent Chairman
Ms. Sarah Boyce	President, CEO & Director
Dr. W. Michael F. Flanagan Ph.D.	Chief Scientific Officer
Mr. John B. Moriarty Jr., ESQ., J.D.	Chief Legal Officer & Corporate Secretary
Ms. Teresa McCarthy	Chief Human Resources Officer
Prof. Mark E. Davis Ph.D.	Scientific Founder, Member of Scientific Advisory Board and Member of Board of Managers
Dr. Frank P. McCormick Ph.D.	Scientific Founder & Member of Scientific Advisory Board
Mr. Charles Calderaro III	Chief Technical Officer
Mr. Eric B. Mosbrooker	Chief Commercial Officer
Ms. Kathleen Gallagher	Chief Program Officer

Important FAQs about investing in RNA Stock from India :

What is Avidity Biosciences share price today?

Avidity Biosciences share price today is $46.49 as on August 16, 2025 at 1:29 AM IST at the close of the market. Avidity Biosciences share today touched a day high of $47.50 and a low of $45.50.

What is the 52 week high and 52 week low for Avidity Biosciences share?

Avidity Biosciences share touched a 52 week high of $56.00 and a 52 week low of $21.51. Avidity Biosciences stock price today, August 16, 2025 at 1:29 AM IST is trending at $46.49, lower by 16.98% versus the 52 week high.

How to invest in Avidity Biosciences Stock (RNA) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Avidity Biosciences on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Avidity Biosciences Shares that will get you 0.0323 shares as per Avidity Biosciences share price of $46.49 per share as on August 16, 2025 at 1:29 AM IST.

What is the minimum amount required to buy Avidity Biosciences Stock (RNA) from India?

Indian investors can start investing in Avidity Biosciences (RNA) shares with as little as ₹87.492 or $1 (as of August 17, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹874.92 in Avidity Biosciences stock (as per the Rupee-Dollar exchange rate as on August 17, 2025). Based on Avidity Biosciences share’s latest price of $46.49 as on August 16, 2025 at 1:29 AM IST, you will get 0.2151 shares of Avidity Biosciences. Learn more about fractional shares .

What are the returns that Avidity Biosciences has given to Indian investors in the last 5 years?

Avidity Biosciences stock has given 107.85% share price returns and 17.06% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your US Stock Investments?